TLR4 and myocardial ischemia: When enclosed within exosomes formed from MSCs, miR-182 specifically targets TLR4, thereby inhibiting the TLR4/NF-κB pathway and activating the PI3K/AKT pathway in the context of cardiac ischemia/reperfusion (I/R) injury.